Head and neck squamous cell carcinoma is highly sensitive to vinorelbine in vitro

Anticancer Research

Volumn 22, Issue 6 A, 2002, Pages 3135-3142

  Erjala, Kaisa ^a   Pulkkinen, Jaakko ^a   Kulmala, Jarmo ^a   Alanen, Kalle ^a   Grenman, Reidar ^a,b  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

Author keywords

Chemosensitivity in vitro; Head and neck squamous cell carcinoma; Vinorelbine

Indexed keywords

NAVELBINE;

APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELL GROWTH; CHEMOSENSITIVITY; CLONOGENESIS; CONCENTRATION RESPONSE; FEMALE; GROWTH INHIBITION; HEAD CANCER; HUMAN; HUMAN CELL; IC 50; MALE; MICROSCOPY; MORPHOLOGY; NECK CANCER; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, SQUAMOUS CELL; CELL DIVISION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; FLOW CYTOMETRY; G2 PHASE; HEAD AND NECK NEOPLASMS; HUMANS; INHIBITORY CONCENTRATION 50; MALE; MITOSIS; TUMOR CELLS, CULTURED; VINBLASTINE;

EID: 0036870187     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Johnson IS, Wright HF, Svoboda GH and Vlantis J: Antitumours principles derived from Vinca rosea Linn:1. Vinca leucoblastine and leurocine. Cancer Res 20: 1016-1022, 1960.
2. Potier P: The synthesis of Navelbine prototype of a new series of vinblastine derivatives. Semin Oncol, 16: 2-4, 1989.
3. Ashizawa T, Miyoshi K, Asada M, Kobayashi E, Okabe M, Morimoto M, Gomi K and Hirata T: Anti-tumour activity of navelbine, a new vinca-alkaloid analog. Gan To Kagaku Ryoho 20: 59-66, 1993.
4. Jassem J, Karnicka-Mlodkowska H, van Pottelsberghe C, van Glabbeke M, Noseda MA, Ardizzoni A, Gozzelino F, Planting A and van Zandwijk N: Phase II study of vinorelbine (Navelbine) in previously treated small cell lung cancer patients. Eur J Cancer 29A: 1720-1722, 1993.
5. Romero A, Rabinovich MG, Vallejo CT, Perez JE, Rodriquez R, Civas MA, Machiavelli M, Lacava JA, Langhi M and Romero-Acuna L: Vinorelbine as first line chemotherapy for metastatic breast carcinoma. J Clin Oncol 12: 336-341, 1994.
6. Gershenson DM, Burke DW, Morris M, Bast RC, Guaspari A, Hohneker J and Wharton JT: A phase I study of a daily x3 schedule of intravenous vinorelbine for refractory epithelial ovarian carcinoma. Gynecol Oncol 70: 404-409, 1998.
7. Cros S, Wright M, Morimoto M, Lataste H, Couzinier JP and Krikorian A: Experimental anti-tumour activity of Navelbine. Semin Oncol 16: 15-20, 1989.
8. Lobert S, Vulevic B and Correia JJ: Interaction of Vinca alkaloids with tubulin: a comparison of vinblastine, vincristine, and vinorelbine. Biochemistry 35: 6806-6814, 1996.
9. Paintrand MR and Pignot I: Navelbine: an ultrastructural study of its effects. J Electron Microsc 32: 115-124, 1983.
10. Forastiere AA, Metch B and Schuller DE: Randomized comparison of cisplatin + fluorouracil and carboplatin + fluorouracil versus methotrexate in advanced squamous cell carcinoma of the head and neck: a South-West oncology group study. J Clin Oncol 10: 1845-1851, 1992.
11. Jacobs C, Lyman G, Valez-Garcia E, Sridhar KS, Knight W, Hochster H, Goodnough LT, Mortimer JE, Einhorn JH and Schacter L: A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 10: 257-263, 1992.
12. Clavel M, Vermorken JB, Cognetti F, Cappelaere P, de Mulder PH, Schornagel JH, Tueni EA, Verweij J, Wildiers J and Clerico M: Randomized comparison of cisplatin, methotrexate, bleomycin, and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. Ann Oncol 5: 521-526, 1994.
13. Huber MH, Lippman SM, Benner SE, Shirinian M, Dimery IW, Dunnington JS and Hong WK: A phase II study of ifosfamide in recurrent squamous cell carcinoma of the head and neck. Am J Clin Oncol 19: 379-382, 1996.
14. Elomaa L, Joensuu H, Kulmala J, Klemi P and Grenman R: Squamous cell carcinoma is highly sensitive to Taxol, a possible new radiation sensitizer. Acta Otol 115: 340-344, 1995.
15. Manfredi JJ, Parness J and Horwitz SB: Taxol binds to cellular microtubules. J Cell Biol 94: 688-696, 1982.
16. Schiff PB, Fant J and Horwitz SB: Promotion of microtubule assembly in vitro by taxol. Nature (London) 277: 665-667, 1979.
17. Leveque D, Jehl F, Quoix E and Breillout F: Clinical pharmacokinetics of vinorelbine alone and when combined with cisplatin. J Clin Pharmacol 32: 1096-1098, 1992.
18. Lansford CD, Grenman R, Bier H, Somers KD, Kim SY, Whiteside TL, Clayman GL, Welkoborsky H-J and Carey TE: Human Cell Culture Vol II, Chapter 28: Head and Neck Cancers. Masters JRW and Palsson B (eds.) Kluwer Academic Publishers, Great Britain pp 185-255, 1999.
19. Grenman R, Burk D, Virolainen E, Buick RN, Church J, Schwartz DR and Carey TE: Clonogenic cell assay for anchorage-dependent squamous carcinoma cell lines using limiting dilution. Int J Cancer 44: 131-136, 1989.
20. Rantanen V, Grenman S, Kulmala J and Grenman R: Comparative evaluation of cisplatin and carboplatin sensitivity in endometrial adenocarcinoma cell lines. Br J Cancer 69: 482-486, 1994.
21. Alanen KA, Klemi PJ, Joensuu H, Kujari H and Pekkala E: Comparison of fresh, ethanol-preserved, and paraffin embedded samples in DNA-flow cytometry. Cytometry 10: 81-85, 1988.
22. Vindelov LL, Christensen IJ and Nissen NI: A detergent-trypsin method for the preparation of nuclei for cytometric DNA analysis. Cytometry 3: 323-327, 1983.
23. Pulkkinen JO, Elomaa L, Joensuu H, Martikainen P, Servomaa K and Grenman R: Paclitaxel-induced apoptotic changes followed by time-lapse videomicroscopy in cell lines established from head and neck cancer. J Cancer Res Clin Oncol 122: 214-218, 1996.